Laetitia Mauti

628 total citations
17 papers, 146 citations indexed

About

Laetitia Mauti is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Laetitia Mauti has authored 17 papers receiving a total of 146 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 5 papers in Surgery. Recurrent topics in Laetitia Mauti's work include Pleural and Pulmonary Diseases (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Research Studies (4 papers). Laetitia Mauti is often cited by papers focused on Pleural and Pulmonary Diseases (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Research Studies (4 papers). Laetitia Mauti collaborates with scholars based in Switzerland, Australia and Germany. Laetitia Mauti's co-authors include Déla Golshayan, Paolo Provero, Ivan Stamenkovic, Marie‐Aude Le Bitoux, Jean‐Christophe Stehle, Karine Baumer, Sacha I. Rothschild, Sabine Schmid, Michael Mark and M. Frueh and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

Laetitia Mauti

16 papers receiving 143 citations

Peers

Countries citing papers authored by Laetitia Mauti

Since Specialization

Citations

This map shows the geographic impact of Laetitia Mauti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laetitia Mauti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laetitia Mauti more than expected).

Fields of papers citing papers by Laetitia Mauti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laetitia Mauti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laetitia Mauti. The network helps show where Laetitia Mauti may publish in the future.

Co-authorship network of co-authors of Laetitia Mauti

This figure shows the co-authorship network connecting the top 25 collaborators of Laetitia Mauti. A scholar is included among the top collaborators of Laetitia Mauti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laetitia Mauti. Laetitia Mauti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Retrospective Analysis of Efficacy and Toxicity of Stereotactic Body Radiotherapy and Surgical Resection of Adrenal Metastases from Solid Tumors 2024 ·Cancers ·(unknown), Hans Gelpke, (unknown), Laetitia Mauti, (unknown), (unknown), (unknown), Daniel R. Zwahlen, Robert Förster, Christina Schröder	1
2	Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment 2024 ·JTO Clinical and Research Reports ·Sabine Schmid, (unknown), (unknown), (unknown), Sacha I. Rothschild, Laura Boos, (unknown), (unknown), Christian Britschgi, Yannis Metaxas, Michael Mark, Patrizia Froesch, Wolf-Dieter Janthur, (unknown), Christine Waibel, (unknown), Martin Früh, Laetitia Mauti	2
3	155P Outcomes in patients with resectable stage III NSCLC who did not have definitive surgery after neoadjuvant treatment: Retrospective analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14 2024 ·ESMO Open ·(unknown), (unknown), Stefanie Hayoz, Matthias Gückenberger, Tobias Finazzi, Isabelle Opitz, Sabine Schmid, Michael Mark, Alfredo Addeo, Laetitia Mauti, DC Betticher, (unknown), Roger Stupp, Alessandra Curioni‐Fontecedro, Solange Peters, M. Frueh, (unknown), Miklos Pless, David König	2
4	Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study 2023 ·Lung Cancer ·(unknown), (unknown), Sabine Schmid, Sämi Schär, (unknown), Oliver Gautschi, Laetitia Mauti, Thomas von Briel, Christine Waibel, Luciano Wannesson, (unknown), Michael Mark, Sacha I. Rothschild, Alfredo Addeo, Wolf-Dieter Janthur, Marco Siano, Laura Boos, Christian Britschgi, Martin Früh	9
5	Only EBUS-Guided Mediastinal Lymph Node Cryobiopsy Enabled Immunotherapy in a Patient with Non-Small Cell Lung Cancer 2023 ·Journal of Clinical Medicine ·Jürgen Hetzel, Laetitia Mauti, (unknown), (unknown), Philip Jermann, Miklos Pless, Lukas Bubendorf, Peter K. Bode, Maik Häntschel	2
6	2191P Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting 2023 ·Annals of Oncology ·Sabine Schmid, (unknown), M. Frueh, (unknown), Sacha I. Rothschild, Christian Britschgi, Laura Boos, (unknown), (unknown), Yannis Metaxas, Michael Mark, (unknown), (unknown), (unknown), Christine Waibel, (unknown), Ferdinando Cerciello, Laetitia Mauti	1
7	SAKK 16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)—A multicenter phase II trial. 2023 ·Journal of Clinical Oncology ·Laetitia Mauti, Tobias Finazzi, (unknown), Adrienne Bettini, David König, Martin Früh, Simon Haefliger, Alfredo Addeo, Michael Mark, Martin Buess, Patrizia Froesch, (unknown), Christine Waibel, Christoph Ackermann, Patrick Dorn, (unknown), Miklos Pless, Matthias Gückenberger, Spasenija Savic Prince, Sacha I. Rothschild	6
8	Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study 2022 ·Lung Cancer ·Alfredo Addeo, Sacha I. Rothschild, (unknown), Martina Schneider, Christine Waibel, Simon Haefliger, Michael Mark, Eugenio Fernández, Nicolas Mach, Laetitia Mauti, Philip Jermann, Ilaria Alborelli, Byron Calgua, Spasenija Savic-Prince, Markus Joerger, Martin Früh	13
9	1540P Real-world analysis of outcomes of first-line chemo-immunotherapy in patients with extensive disease small cell lung cancer (ED-SCLC) 2022 ·Annals of Oncology ·Núria Zellweger, Sabine Schmid, (unknown), Christine Waibel, Ferdinando Cerciello, (unknown), Michael Mark, Adrienne Bettini, (unknown), (unknown), (unknown), Fabrice Helfenstein, M. Frueh, Laetitia Mauti, Sacha I. Rothschild	3
10	Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. 2021 ·Journal of Clinical Oncology ·Alfredo Addeo, Markus Joerger, Sacha I. Rothschild, E.I. Eboulet, Gilles Godar, (unknown), Simon Haefliger, Michael Mark, Eugenio Fernández, Nicolas Mach, Laetitia Mauti, M. Frueh	4
11	Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort 2020 ·Cancer Immunology Immunotherapy ·Sabine Schmid, Laetitia Mauti, Alex Friedlaender, (unknown), Sacha I. Rothschild, Hasna Bouchaab, (unknown), Christian Britschgi, David König, Luciano Wannesson, Wolf-Dieter Janthur, Sämi Schär, (unknown), Alfredo Addeo, Wolfram Jochum, Martin Früh	6
12	Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L)1 targeting monoclonal antibodies 2019 ·Annals of Oncology ·(unknown), Sacha I. Rothschild, Laetitia Mauti, Sabine Schmid, (unknown), Alessandra Curioni‐Fontecedro, M. Frueh, Markus Joerger	9
13	Current and future developments of immunotherapy in lung cancer 2018 ·memo - Magazine of European Medical Oncology ·Laetitia Mauti, Tobias Finazzi, Martin Früh, Miklos Pless, Alfred Zippelius, Sacha I. Rothschild	1
14	Pembrolizumab (pembro) for relapsed malignant pleural mesothelioma (MPM): Outcomes in real-life setting in Australia (AUS) and Switzerland (CH) 2017 ·Annals of Oncology ·Laetitia Mauti, Gareth Rivalland, Dirk Klingbiel, Steven Kao, Sabine Schmid, Anna K. Nowak, Oliver Gautschi, Brett Hughes, (unknown), Nick Pavlakis, Hasna Bouchaab, Kenneth J. O’Byrne, Sacha I. Rothschild, Prudence A. Russell, (unknown), Bibhusal Thapa, Miklos Pless, Roger von Moos, Yannis Metaxas, Thomas John	1
15	Pembrolizumab as second or further line treatment in relapsed malignant pleural mesothelioma: A Swiss registry 2017 ·Annals of Oncology ·Laetitia Mauti, Dirk Klingbiel, Sabine Schmid, Hasna Bouchaab, (unknown), Oliver Gautschi, Sacha I. Rothschild, Markus Loeffler, Patrizia Froesch, Ulf Petrausch, (unknown), Walter Mingrone, (unknown), (unknown), Miklos Pless, Roger von Moos, Yannis Metaxas	3
16	Diagnostik, Therapie und Nachsorge beim Hodenkarzinom 2016 ·Praxis ·(unknown), Laetitia Mauti, Miklos Pless	0
17	Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation 2011 ·Journal of Clinical Investigation ·Laetitia Mauti, Marie‐Aude Le Bitoux, Karine Baumer, Jean‐Christophe Stehle, Déla Golshayan, Paolo Provero, Ivan Stamenkovic	83

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact